Search results
Found 8464 matches for
Paper by NJ White et al, PLoS Medicine, in press. Using available pharmacokinetic information from healthy volunteers, the treatment of malaria, the chronic treatment of rheumatological conditions and the toxicokinetics of chloroquine in self-poisoning, the authors predict exposures and safety margins in the high dose chloroquine and hydroxychloroquine COVID-19 prevention and treatment regimens currently under evaluation. These regimens are predicted to have reasonable safety margins. Large, well conducted randomised clinical trials with appropriate monitoring are required to determine if chloroquine and hydroxychloroquine have preventive or treatment efficacy in COVID-19 and acceptable safety. Current recommendations for their use outside of clinical trials are not justified at this time.
Nicholas White
COVID-19 Investigators Principal Investigators Research Scientists
FRS Nicholas White - Professor of Tropical Medicine
Andrea Soult
Andrea Soult - Research Pharmacist
Thitthiphone Olinh
Thitthiphone Olinh - Research Pharmacist
Naomi Waithira
COVID-19 Investigators Graduate Students Research Scientists
Naomi Waithira - MORU head of Data Management